Last news
WeRide to Launch GXRs and Robobus in Singapore as part of Grab's New Ai.R Autonomous Service

WeRide to Launch GXRs and Robobus in Singapore as part of Grab's New Ai.R Autonomous Service

Notified -...

Axi Announces Retirement of Chief Commercial Officer Louis Cooper

Axi Announces Retirement of Chief Commercial Officer Louis Cooper

Notified -...

OPEC Fund mobilizes over US$1 billion to advance sustainable development

OPEC Fund mobilizes over US$1 billion to advance sustainable development

Notified -...

WHO Disenfranchises the Public from Tobacco Control Conference as Registration Barriers Reach "Insane" Levels

WHO Disenfranchises the Public from Tobacco Control Conference as Registration Barriers Reach "Insane" Levels

Notified -...

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Notified -...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -...

1 ... 66 67 68 69 70 71 72 73 74 ... 970
menu
menu